EMA asks for more in­for­ma­tion af­ter safe­ty sig­nal aris­es for GLP-1s, semaglu­tide in thy­roid can­cer

The Eu­ro­pean Med­i­cines Agency is con­cerned there could be a po­ten­tial link be­tween thy­roid can­cer and the use of glucagon-like pep­tide-1 (GLP-1) re­cep­tor ag­o­nists, which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER